Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

AdipoGen Ixazomib citrate MLN9708
SDP

Supplier:  AdipoGen AGCR13671M001

Encompass_Preferred

Chemical. CAS 1239908-20-3. Formula C20H23BCl2N2O9. MW 517.1. Synthetic. Potent selective and reversible proteasome inhibitor all proteolytic subunits. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome IC50=3.4nM. Cross-reacts and inhibits the trypsin-like beta2 subunit IC50=3.5µM and the caspase-like/peptidyl-glutamyl peptide-hydrolyzing PGPH beta1 subunit IC50=0.03µM. Anticancer compound effective in cell-based assays, in xenografts and against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma. Prodrug that rapidly hydrolyzes to MLN2238 AG-CR1-3670. Exhibits improved pharmacodynamics and antitumor activity compared to bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.

Catalog No. 50-256-2239


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.